Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01285024 · ClinicalTrials.gov registry record · NA

A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty

A NA study, sponsored by The Cleveland Clinic.

Completed
Registry status
NA
Development phase
109
Enrollment target

NCT01285024: Completed NA study, sponsored by The Cleveland Clinic.

NCT01285024 is a NA study that has completed, run by The Cleveland Clinic. The registered enrollment target is 109 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01285024, a NA study, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
NA
Development phase
109 participants
Enrollment target

Study Summary

This is a prospective, randomized, controlled, single-center study to assess the effectiveness of Vitagel, a surgical hemostat, in primary unilateral total hip arthroplasty (THA). This will be an inter-patient controlled study involving one-hundred-ten subjects. Vitagel will be used in a randomly selected cohort of fifty-five patients undergoing primary unilateral THA procedures; a control group of fifty-five patients will not receive Vitagel or any other hemostatic agent except those that are standard during a primary THA. The study will evaluate the effectiveness of Vitagel in reducing intra- and post-operative bleeding.

Primary Outcome

Measure Title: Units of transfusion required

Interventions

  • DEVICE Vitagel

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 2010-12
Est. Completion 2014-12
Phase NA
The Cleveland Clinic

688 total trials

What the finished NCT01285024 record still lists

NCT01285024 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 1 intervention - of which Vitagel is the first listed.

NCT01285024 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01285024 about?

NCT01285024 is a clinical study titled "A Prospective Study to Evaluate the Effectiveness of a Haemostatic Agent in Primary Unilateral Total Hip Arthroplasty". This is a prospective, randomized, controlled, single-center study to assess the effectiveness of Vitagel, a surgical hemostat, in primary unilateral total hip arthroplasty (THA). This will be an inter-patient controlled study involving one-hundred-ten subjects. Vitagel will be used in a randomly se...

What is the current status of trial NCT01285024?

This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2010-12. Estimated completion is 2014-12.

What interventions are being tested in trial NCT01285024?

The interventions under investigation include: Vitagel (DEVICE).

Who is sponsoring clinical trial NCT01285024?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01285024's enrollment target sits among peer trials

109 825th of 2000 higher than 1,176 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02421380 · 109 participants · NA

    Characterization of Hyperpolarized Pyruvate MRI Reproducibility

  • NCT04526600 · 109 participants · NA

    Fidgeting and Attentional and Emotional Regulation in ADHD

  • NCT04835584 · 109 participants · Phase 1

    KRT-232 and TKI Study in Chronic Myeloid Leukemia

  • NCT06626516 · 109 participants · Phase 1

    Tebentafusp-tebn With LDT in Metastatic UM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01285024, the US trial registry maintained by the National Library of Medicine. NCT01285024 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.